- likes
- 204
- comments
- 3
Post
Researchers are pushing the boundaries of molecular residual disease (MRD) research. Today, we're expanding the Illumina MRD research ecosystem with Illumina duplex sequencing technology, designed to support ultra-sensitive whole-genome ctDNA monitoring. Built on the foundation of Illumina WGS oncology research workflows, the new technology is designed to: 🔬 Detect ultra-low-frequency variants across the genome 🔬 Achieve Q65+ accuracy with NovaSeq™ X and DRAGEN™ informatics 🔬 Support sensitivity at 2.5 ppm 🔬 Enable longitudinal ctDNA monitoring with 10 ng cfDNA input Together with Illumina WGS Oncology Prep, researchers now have complementary whole-genome sequencing workflow options to support MRD research programs from tumor fingerprinting through ultra-sensitive monitoring. Learn more and register interest in early access: https://bit.ly/4iGvfh5